A Study of Hospital-at-Home for People Receiving Tarlatamab
NCT06957314
This study is recruiting at 7 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to find out whether a Hospital-at-Home (HaH) program is a more efficient way to monitor people's health after receiving tarlatamab than monitoring in the hospital (inpatient).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Small-cell Lung Cancer
- Small Cell Lung Carcinoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Last updated on ClinicalTrials.gov
- October 9, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New Jersey · 3
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) · Basking Ridge, NJ
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, NJ
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, NJ
New York · 4
- Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities) · Commack, NY
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, NY
- Memorial Sloan Kettering Cancer Center (All Protocol Activites) · New York, NY
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) · Uniondale, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.